Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Summit Therapeutics Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.74, while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| JPIN | SMMT | |
|---|---|---|
52-Week High | $76.96 | $29.32 |
52-Week Low | $63.14 | $13.05 |
Market Cap | — | $10.48B |
Sector | — | Health |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.11, down 0.5% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF provides broad exposure to international large-cap value stocks, utilizing a smart-beta strategy for diversification. A dividend of $0.91 is scheduled for payment on June 25, 2026.
The ETF's outlook is supported by its diversified international equity approach, though it faces risks from global market volatility and currency fluctuations. Key resistance is at $74, with support at $73. The bullish technical setup suggests potential for near-term gains, but investors should weigh the inherent risks of international investing.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
